(San Francisco) -- Mytrus, an innovative clinical technology and services company for medical and pharmaceutical research, today announced that the University of Alabama at Birmingham (UAB) will use its iPad® application in an upcoming pilot study supported by the U.S. Department of Health & Human Services Agency for Healthcare Research and Quality. UAB is evaluating how digital tools might simplify enrollment and enhance patient understanding during the informed consent process. Kenneth G. Saag, MD, Msc, professor in the UAB Department of Medicine, will lead the study.
For more specific information on UAB's usage of the Mytrus iPad application, read UAB's article, “UAB studying high tech way to secure informed consent in research trials” by Bob Shepard, published earlier this month.
Using animation and other visual imagery, the Mytrus iPad application is the first in the industry to condense the complex and critical disclosure information required at the start of a clinical trial into an easy-to-understand, digitized format. This new approach not only helps patients better understand the clinical trial process; it helps researchers gain valuable insight into the speed and effectiveness of the informed consent process in multi-center studies.
"The Mytrus application gives study sponsors a window into the informed consent process that they've never had before," said Anthony Costello, CEO of Mytrus. "Like many sponsors we work with, the University of Alabama at Birmingham also recognizes that increasing a patient's understanding and comfort level during consent is the best way to retain highly motivated and protocol compliant patients throughout the study."
About the Mytrus Application
The Mytrus mobile application for tablets facilitates quick patient enrollment and enables patient supplied data to be fed directly into a clinical trial database. It helps researchers streamline the clinical trial data collection process and makes it easy to conduct a clinical trial in sites where affected populations are present – no matter how remote that location might be. Data entered at the site is quickly synced with the clinical trial database, giving researchers anywhere in the world a better methodology for monitoring potential adverse effects and patient progress.
Founded in 2009, Mytrus is a privately held e-clinical technology company specializing in patient-centered electronic informed consent and data collection tools. After receiving the first FDA approvals for remote electronic consent and virtual data collection, Mytrus has gone on to develop new technologies for patients including ePRO and EDC tools usable from home and mobile devices, bio-sample consent tracking technology, site training and e-learning applications, and patient home dashboards for tracking clinical study progress and data. Mytrus also holds an exclusive patent for conducting virtual clinical trials in the US. Mytrus investors include BioClinica and inVentiv Health.